

Form PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93)		ATTORNEY'S DOCKET NUMBER B45122
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/554860</b>
INTERNATIONAL APPLICATION NO. PCT/EP98/07521	INTERNATIONAL FILING DATE 16 November 1998	PRIORITY DATE CLAIMED 19 November 1997
TITLE OF INVENTION <b>RECOMBINANT ALLERGEN WITH REDUCED ENZYMATIC ACTIVITY</b>		
APPLICANT(S) FOR DO/EO/US <b>Claudine BRUCK, Alex BOLLEN, Paul JACOBS and Marc MASSAER</b>		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

**Items 11. to 16. below concern other document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.  
☒ Please amend the specification by inserting before the first line the sentence: This is a 371 of International Application PCT/EP98/07521, filed 16 November 1998, which claims benefit from the following Foreign Application: GB 9724531.0 filed 19 November 1997.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:


09554860-051900

US APPLICATION NO. (if known see 37 CFR 1.50) <b>09/554860</b>		INTERNATIONAL APPLICATION NO. PCT/EP98/07521		ATTORNEYS DOCKET NO. B45122	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY	
<b>Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)):</b>					
Search Report has been prepared by the EPO or JPO .....\$840.00					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) .....\$670.00					
No International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .....\$690.00					
Neither International Preliminary Examination Fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$970.00					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$96.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$840.00</b>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<b>\$0.00</b>	
Claims	Number Filed	Number Extra	Rate		
Total claims	<b>21 - 20 =</b>	<b>1</b>	<b>1 x \$18.00</b>	<b>\$18.00</b>	
Independent claims	<b>7 - 3 =</b>	<b>4</b>	<b>4 x \$78.00</b>	<b>\$312.00</b>	
Multiple dependent claims (if applicable)			<b>+ \$260.00</b>	<b>\$260.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$590.00</b>	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				<b>\$</b>	
<b>SUBTOTAL =</b>				<b>\$1430.00</b>	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +				<b>\$</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$1430.00</b>	
				Amount to be refunded	\$
				charged	\$

- a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-2570 in the amount of **\$1430.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.
- d. ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:  
SMITHKLINE BEECHAM CORPORATION  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5024  
Facsimile (610) 270-5090

  
SIGNATURE  
Zoltan Kerekes  
NAME  
38,938  
REGISTRATION NO.

09/554860

"EXPRESS MAIL CERTIFICATE" 526 Rec'd PCT/PTC 19 MAY 2000  
"EXPRESS MAIL" MAILING LABEL NUMBER EL229502551US  
DATE OF DEPOSIT 19 May 2000

Attorney Docket No. B45122

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruck, et al. 19 May 2000  
Int'l. App. No.: PCT/EP98/07521 Group Art Unit No.: Unknown  
Int'l. Filing Date: 16 November 1998 Examiner: Unknown  
For: RECOMBINANT ALLERGEN WITH REDUCED ENZYMATIC  
ACTIVITY

Assistant Commissioner of Patents  
Box: PCT  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Preliminary to the examination of this application, applicants respectfully request amendment of the above-identified application as follows:

IN THE CLAIMS:

Please cancel claim 21.

Please amend claim 18.

18. (Amended) A vaccine comprising a recombinant mutant allergen as claimed in any one of claims 1 to [17] 16, and an adjuvant.

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/EP98/07521. Applicants have cancelled claim 21 and amended claim 18 to put the claims in conformity with U.S. practice.

09/554860 "051900

Intl. App. No.: PT/EP98/07521  
Docket No. B45122

No new matter has been introduced.

Respectfully submitted,



Zoltan Kerekes  
Attorney for Applicants  
Registration No. 38,938

SMITHKLINE BEECHAM CORPORATION  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5024  
Facsimile (610) 270-5090

N:\zk\apps\b45122\Preamd.doc

006T50"09845960

RECOMBINANT ALLERGEN WITH REDUCED ENZYMATIC ACTIVITY

The present invention relates to novel therapeutic formulations, said formulations being effective in the reduction of allergic responses to specific allergens. Further, this  
5 invention relates to novel polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. In particular, novel vaccines are provided comprising polypeptides and to their use in the treatment of humans suffering from allergies or prevention of individuals at risk from allergies, preferably said vaccines comprising a recombinant mutant *Dermatophagoides*  
10 *pteronyssinus* allergen Der P1.

Allergic responses in humans are common, and may be triggered by a variety of allergens. Allergic individuals are sensitised to allergens, and are characterised by the presence of high levels of allergen specific IgE in the serum, and possess allergen  
15 specific T-cell populations which produce Th2-type cytokines (IL-4, IL-5, and IL-13). Binding of IgE, in the presence of allergen, to Fc receptors present on the surface of mastocytes and basophils, leads to the rapid degranulation of the cells and the subsequent release of histamine, and other preformed and neoformed mediators of the inflammatory reaction. In addition to this, the stimulation of the T-cell recall response  
20 results in the production of IL-4 and IL-13, together cooperating to switch B-cell responses further towards allergen specific IgE production. For details of the generation of early and late phase allergic responses see Joost Van Neeven *et al.*, 1996, Immunology Today, 17, 526. In non-allergic individuals, the immune response to the same antigens may additionally include Th1-type cytokines such as IFN- $\gamma$ . These  
25 cytokines may prevent the onset of allergic responses by the inhibition of high levels of Th2-type immune responses, including high levels of allergen specific IgE. Importantly in this respect, is the fact that IgE synthesis may be controlled by an inhibitory feedback mechanism mediated by the binding of IgE/allergen complexes to the CD23 receptor on B-cells (Luo *et al.*, J.Immunol., 1991, 146(7), 2122-9; Yu *et al.*, 1994, Nature,  
30 369(6483):753-6). In systems that lack cellular bound CD23, this inhibition of IgE synthesis does not occur.

Current strategies in the treatment of such allergic responses include means to prevent the symptomatic effects of histamine release by anti-histamine treatments and/or local administration of anti-inflammatory corticosteroids. Other strategies which are under development include those which use the hosts immune system to prevent the

5 degranulation of the mast cells, Stanworth *et al.*, EP 0 477 231 B1. Other forms of immunotherapy have been described (Hoyne *et al.*, J.Exp.Med., 1993, 178, 1783-1788; Holt *et al.*, Lancet, 1994, 344, 456-458).

Some common allergens present in bee venom, house dust mite emanations and parasite

10 proteins have been found to induce mast cell degranulation, and to stimulate interleukin-4 synthesis and secretion, even in the absence of allergen-specific IgE (Machado *et al.*, 1996, Eur.J.Immunol. 26, 2972-2980). This non-immunological degranulation by proteolytic allergens, such as bee venom phospholipase A2 or proteases associated with house dust mite emanations is dependent on enzymatic

15 activity.

The present invention provides recombinant mutant allergens having significantly reduced proteolytic activity relative to the wild-type proteolytically active allergen, as well as nucleic acids encoding the same, and their use as a prophylactic or

20 immunotherapeutic agent against allergy. A preferred allergen is the house dust mite allergen Der p1.

The present invention relates to the provision of formulations for the treatment and prophylaxis of allergy, by providing means to down-regulate the production of IgE, as

25 well as modifying the cell mediated response to the allergen, through a shift from a Th2 type to a Th1 type of response (as measured by the reduction of ratio of IL-4 : IFN- $\gamma$  producing DerP1 specific T-cells, or alternatively a reduction of the IL-5:IFN- $\gamma$  ratio). This is achieved by the provision and use of recombinant mutant allergens with impaired enzymatic activity.

30 DerP1, a group 1 protease allergen of the house dust mite *Dermatophagoides pteronyssinus* (Topham *et al.*, 1994, Protein Engineering, 7, 7, 869-894; Simpson *et al.*, 1989, Protein Sequences and Data Analyses. 2, 17-21) is one such allergen. It is a 30

KDa protein and has been cloned and sequenced (Chua *et al.*, 1988, J.Exp.Med., 167, 175-182). It is known to contain 222 amino acid residues in the mature protein. The sequence of DerP1 shares 31% homology to Papain, and importantly shares homology in the enzymatically active regions, most notably the Cys34-His170 ion pair (Topham *et al.*, *supra*). DerP1 is produced in the mid-gut of the mite, where its role is probably related to the digestion of food. Up to 0.2 ng of proteolytically active DerP1 is incorporated into each fecal pellet, each around 10-40 µm in diameter and, therefore, easily inspired into the human respiratory tract. Overnight storage of purified DerP1 preparations at room temperature results in almost complete loss of enzymatic activity due to autoproteolytic degradation (Machado *et al.*, 1996, Eur.J.Immunol. 26, 2972-2980).

DerP1 has been found to cleave the low affinity immunoglobulin IgE Fc receptor from the surface of human B lymphocytes (CD23, Hewitt *et al.*, 1995, J.Exp.Med., 182, 1537-1544) and CD25 (Schultz *et al.*, J.Exp.Med, 1998, 187(2):271-5) the alpha subunit of the human T cell interleukin-2 receptor. Cleavage of the receptor from the B cell surface was associated with a parallel increase in soluble CD23 in the culture supernatant. It has been suggested that the loss of cell surface CD23 from IgE-secreting B cells may promote and enhance IgE immune responses by ablating the important inhibitory feedback mechanism that normally limits IgE synthesis (Hewitt *et al.*, 1995, J.Exp.Med., 182, 1537-1544). Furthermore, since soluble CD23 has been shown to promote IgE production, fragments of CD23 released by DerP1 may directly enhance the synthesis of IgE. In addition to the effects of CD23 cleavage, the cleavage of CD25 from the surface of T-cells induces a decrease in proliferation and INF-gamma secretion, which, consequently, may bias the immune response toward a Th2 type response. Recent papers which relate to the DerP1 antigen are Machado *et al.* Eur. J. Immunol. (1996) 26: 2972-2980; Hewitt *et al.*, J. Exp. Med. (1995) 182: 1537-1544; and Schulz *et al.* Eur. J. Immunol. (1995) 25: 3191-3194.

Other mutant allergens having reduced proteolytic activity which form part of the present invention may be based upon other group I cyteine proteases, such as Der f1 from *Dermatophagoides farinae* (80% homology to DerP1), as well as the groups III allergens (serine proteases) including DerpIII (Stewart *et al.*, 1992, Immunology, 75,

29-35) and DerpIV (Yaseuda *et al.*, 1993, Clin.Exp.Allergy, 23, 384-390); and the group IV allergens (amylases).

5 The allergens of the present invention are recombinantly produced. Der p1 proteolytic activity can be impaired by introducing mutations into the cDNA or genomic DNA, either at the enzymatically active site, or at the site of cleavage between the propeptide and the mature molecule. Said mutant allergen having the following advantages over the wild-type allergen: 1) increases the Th1-type aspect of the immune responses in comparison to those stimulated by the wild type allergen, thereby leading to the suppression of allergic potential of the vaccinated host, and 2) having reduced allergenicity thus being more suitable for systemic administration of high doses of the immunogen, 3) will induce DerP1 specific IgG which compete with IgE for the binding of native DerP1.

15 The allergens of the present invention are also more stable than isolated or recombinant active DerP1, as measured by the lack of autoproteolytic degradation. Thus, the present invention also provides allergens which are stable compared to the wild-type form of the allergen, said allergens having significantly reduced proteolytic activity and being substantially full length proteins, optionally said allergens further comprising the pro-form of allergen.

20 One aspect of the present invention provides a nucleic acid encoding mutated Der p1 as set out above, and a further aspect of the invention provides mutated Der p1 *per se*. A yet further aspect of the present invention provides substantially stable recombinant DerP1. Said stable DerP1 being of substantially full length mature protein, or mature protein further comprising the pro-DerP1 section. The term "stable" in the context of the present invention is a product which does not undergo a substantial amount of decomposition by autoproteolysis when incubated overnight at room temperature in comparison to proteolytically active wild-type DerP1, as evidenced by SDS PAGE analysis.



A still further aspect of the invention provides a process for the preparation of a mutated Der p1 protein, which process comprises expressing DNA encoding the said protein in a recombinant host cell and recovering the product.

- 5 A DNA molecule encoding a mutated Der p1 (or other mutated allergen) forms a further aspect of the invention and can be synthesized by standard DNA synthesis techniques, such as by enzymatic ligation as described by D.M. Roberts et al in Biochemistry 1985, 24, 5090-5098, by chemical synthesis, by in vitro enzymatic polymerization, or by a combination of these techniques.
- 10 Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50ml or less. Enzymatic ligation of DNA
- 15 fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer, such as 0.05M Tris (pH 7.4), 0.01M MgCl<sub>2</sub>, 0.01M dithiothreitol, 1mM spermidine, 1mM ATP and 0.1mg/ml bovine serum albumin, at a temperature of 4°C to ambient, generally in a volume of 50ml or less. The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester,
- 20 phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982), or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W.
- 25 Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H. Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the American Chemical Society, 1981, 103, 3185; S.P. Adams et al., Journal of the American Chemical Society, 1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes et al., EMBO
- 30 Journal, 1984, 3, 801.

Alternatively, the coding sequence can be derived from DerP1 mRNA, using known techniques (e.g. reverse transcription of mRNA to generate a complementary cDNA strand), and commercially available cDNA kits.

- 5 The invention is not limited to the specifically disclosed sequence, but includes any proteolytic allergen which has been mutated to remove some or all of its proteolytic activity, whilst retaining the ability to stimulate an immune response against the wild-type allergen. The proteolytic activity of the mutant allergens may be compared to the wild type by a CD23 cleavage assay according to Shultz *et al.*, 1995, European Journal  
10 of Immunology, 25, 3191-3194), or enzymatic degradation of substrates described in Machado et al., 1996, Eur.J.Immunol., 26, 2972-2980. The immunogenicity of the mutant allergen may be compared to that of the wild-type allergen by various immunologicals assays. The cross-reactivity of the mutant and wild-type allergens may be assayed by *in vitro* T-cell assays after vaccination with either mutant or wild-type  
15 allergens. Briefly, splenic T-cells isolated from vaccinated animals may be restimulated *in vitro* with either mutant or wild-type allergen followed by measurement of cytokine production with commercially available ELISA assays, or proliferation of allergen specific T cells may be assayed over time by incorporation of tritiated thymidine. Also the immunogenicity may be determined by ELISA assay, the details of which may be  
20 easily determined by the man skilled in the art. Briefly, two types of ELISA assay are envisaged. First, to assess the recognition of the mutant DerP1 by sera of mice immunized with the wild type Der p1; and secondly by recognition of wild type DerP1 allergen by the sera of animals immunised with the mutant allergen. Briefly, each wells will be coated with 100 ng of purified wild type or mutated Der p1 overnight at 4°C.  
25 After incubating with a blocking solution (TBS-Tween 0.1% with 1% BSA) successive dilutions of sera will be incubated at 37°C for 1 hour. The wells are washed 5 times, and total IgG revealed by incubating with an anti-IgG antibody conjugated with Alkaline phosphatase.
- 30 The reduction of enzymatically active allergen or DerP1 may be performed by introducing mutations into the native sequence before recombinantly producing the inactivated mutants. This may be achieved by: introducing substitutions, deletions, or additions into the active sites: by inserting, deleting, or substituting residues in regions

of processing the inactive pro-enzyme into the active mature protein; or by altering the three dimensional structure of the protein such that enzymatic activity is lost, this may be achieved, amongst others, by expressing the protein in fragments, or by deleting cysteine residues involved in disulphide bridge formation, or by deleting or adding  
5 residues such that the tertiary structure of the protein is substantially altered. Alternatively, mutations may be generated with the effect of altering the interaction between the Cys and the His residues, at positions 34 and 170 of the mature protein respectively (corresponding to positions 132 and 268 of the pre-pro-protein respectively) in the resultant fully folded recombinant protein.

10

The invention is illustrated herein, but not limited to, three specific mutations which are are given as examples of proteolytically inactive DerP1. First, the enzymatic activity of DerP1 is abrogated by substituting a Cysteine residue in the active site for an alanine. This substitution occurs at Cys132→Ala132 of the pro-DerP1 protein sequence, and is  
15 set out in SEQ ID NO. 1. Second, the DerP1 allergen is recombinantly expressed and retained in its inactive pro-protein form by deletion of four amino acid residues at the linker region between the pro- and mature proteins. This deletion removes amino acid residues NAET from the site 96-99 inclusive, from the Pro-DerP1 protein sequence. This sequence is set out in SEQ ID NO. 2. Third, enzymatic activity of DerP1 is  
20 abrogated by substituting a Histidine residue in the active site for an alanine. This substitution occurs at His268→Ala268 of the pro-DerP1 protein sequence, and is set out in SEQ ID NO. 3.

The active sites of each wild-type enzymatic allergen may be determined from the  
25 literature, or by reference to homologues. For example, the active sites of DerP1, being a cysteine protease, may be putatively inferred by reference to other known cysteine proteases such as Papain. DerP1 shares essential structural and mechanistic features with other papain-like cysteine proteinases, including cathepsin B. The active site thiolate-imidazolium ion pair comprises the side chains of Cys34 and His170 (Topham  
30 et al., 1994, Protein Engineering, 7, 7, 869-894).

Mutated versions of Der p 1 may be prepared by site-directed mutagenesis of the cDNA which codes for the Der p 1 protein by conventional methods such as those described by

G. Winter et al in Nature 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter et al in Biochem. Soc. Trans., 1984, 12, 224-225.

5

The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982-1989.

10 In particular, the process may comprise the steps of:

1. Preparing a replicable or integrating expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes the said mutant Der p1 protein;
2. Altering the enzymatic activity of the resultant protein by one of the following techniques: replacing the cysteine or histidine residues (or other residues interacting with other residues within the active site) from the active site with an alanine residue using site directed mutagenesis; replacement of a cDNA fragment by a pair of oligonucleotides whose sequence differ from the natural one; or alternatively, deleting four residues at the junction between the propeptide and the mature enzyme using site directed mutagenesis
3. Transforming a host cell with the said vector
4. Culturing the transformed host cell under conditions permitting expression of the DNA polymer to produce the protein; and
5. Recovering the protein.

25

The term 'transforming' is used herein to mean the introduction of foreign DNA into a host cell by transformation, transfection or infection with an appropriate plasmid or viral vector using e.g. conventional techniques as described in Genetic Engineering; Eds. S.M. Kingsman and A.J. Kingsman; Blackwell Scientific Publications; Oxford, England, 1988. The term 'transformed' or 'transformant' will hereafter apply to the resulting host cell containing and expressing the foreign gene of interest.

30

The expression vector is novel and also forms part of the invention.

The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules  
5 which, together with said linear segment encode the desired product, such as the DNA polymer encoding the Der p 1 protein under ligating conditions.

Thus, the DNA polymer may be preformed or formed during the construction of the vector, as desired.

10

The choice of vector will be determined in part by the host cell, which may be prokaryotic or eukaryotic. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses.

15 The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis et al cited above.

The recombinant host cell is prepared, in accordance with the invention, by  
20 transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis et al cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.

25 The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as E. coli may be treated with a solution of  $\text{CaCl}_2$  (Cohen et al, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of  $\text{RbCl}$ ,  $\text{MnCl}_2$ , potassium acetate and glycerol, and then with 3-[N-morpholino]-propane-sulphonic acid,  $\text{RbCl}$  and glycerol. Mammalian cells in culture may be transformed by calcium  
30 co-precipitation of the vector DNA onto the cells, by lipofection, or by electroporation. The invention also extends to a host cell transformed with a replicable expression vector of the invention.

Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis et al and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C.

5

The product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium or  
10 from cell free extracts. Conventional protein isolation techniques include selective precipitation, absorption chromatography, and affinity chromatography including a monoclonal antibody affinity column.

Alternatively, the expression may be carried out either in insect cells using a suitable  
15 vector such as a baculovirus, in transformed drosophila cells, or mammalian CHO cells. The novel protein of the invention may also be expressed in yeast cells as described for the CS protein in EP-A-0 278 941.

The vaccine of the invention comprises an immunoprotective amount of the mutated  
20 version of the Der p1 (or other) allergenic protein. The term "immunoprotective" refers to the amount necessary to elicit an immune response against a subsequent challenge such that allergic disease is averted or mitigated. In the vaccine of the invention, an aqueous solution of the protein can be used directly. Alternatively, the protein, with or without prior lyophilization, can be mixed, adsorbed, or covalently linked with any of  
25 the various known adjuvants. Preferably, the adjuvant may be a preferential inducer of Th1-type immune responses.

An immune response is generated to an antigen through the interaction of the antigen with the cells of the immune system. The resultant immune response may be broadly  
30 distinguished into two extreme categories, being a humoral or cell mediated immune responses (traditionally characterised by antibody and cellular effector mechanisms of protection respectively). These categories of response have been termed Th1-type responses (cell-mediated response), and Th2-type immune responses (humoral

response). In mice Th1-type responses are characterised by the generation of antibodies of the IgG2a subtype, whilst in the human these correspond to IgG1 type antibodies. Th2-type immune responses are characterised by the generation of a broad range of immunoglobulin isotypes including in mice IgE, IgG1, IgA, and IgM.

5

It can be considered that the driving force behind the development of these two types of immune responses are cytokines, a number of identified protein messengers which serve to help the cells of the immune system and steer the eventual immune response to either a Th1 or Th2 response. Thus Th1-type cytokines induce a cell mediated immune  
10 response to the given antigen, whilst Th2-type cytokines induce a humoral immune response to the antigen.

It is important to remember that the distinction of Th1 and Th2-type immune responses is not absolute. In reality an individual will support an immune response which is  
15 described as being predominantly Th1 or predominantly Th2. However, it is often convenient to consider the families of cytokines in terms of that described in murine CD4 T cell clones by Mosmann and Coffman (*Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p145-173*). Traditionally, Th1-  
20 type responses are associated with cell mediated effector mechanisms such as cytotoxic lymphocytes (CTL) and can be characterised by the production of the INF- $\gamma$  and IL-2 cytokines by T-lymphocytes. Other cytokines often directly associated with the induction of Th1-type immune responses are not produced by T-cells, such as IL-12. In contrast, Th2- type responses are associated with humoral mechanisms and the secretion  
25 of IL-4, IL-5, IL-6, IL-10 and tumour necrosis factor- $\beta$  (TNF- $\beta$ ).

It is known that certain vaccine adjuvants are particularly suited to the stimulation of either Th1 or Th2 - type cytokine responses. This weighting of cytokine production translates into the generation of either a predominantly Th1-type or Th2-type immune  
30 responses. Traditionally the best indicators of the Th1:Th2 balance of the immune response after a vaccination or infection includes direct measurement of the production of Th1 or Th2 cytokines by T lymphocytes *in vitro* after restimulation with antigen, and measurement of the IgG1:IgG2a ratio of antigen specific antibody responses.

Thus, a Th1-type adjuvant is one which stimulates isolated T-cell populations to produce high levels of Th1-type cytokines when re-stimulated with antigen *in vitro*, and induces antigen specific immunoglobulin responses associated with Th1-type mechanisms (IgG2a in mice, IgG1 in the human).

Adjuvants include, but are not limited to, aluminium hydroxide, muramyl dipeptide and saponins such as Quil A, 3D-MPL (3-O-deacylated monophosphoryl lipid A), or TDM. As a further exemplary alternative, the protein can be encapsulated within microparticles such as liposomes. Particularly preferred adjuvants which preferentially stimulate Th1-type immune responses are combinations of 3D-MPL and QS21 (EP 0 671 948 B1), oil in water emulsions comprising 3D-MPL and QS21 (WO 95/17210), 3D-MPL formulated with other carriers (EP 0 689 454 B1), or QS21 formulated in cholesterol containing liposomes (WO 96/33739), or immunostimulatory oligonucleotides (WO 96/02555). In yet another exemplary alternative, the protein can be conjugated to a carrier protein which is capable of providing T-cell help to the generation of the anti-allergen immune response, such as tetanus toxoid. Use of Quil A is disclosed by Dalsgaard *et al.*, Acta Vet Scand, 18:349 (1977).

Vaccine preparation is generally described in New Trends and Developments in Vaccines, Voller *et al.* (eds.), University Park Press, Baltimore, Maryland, 1978. Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, US Patent 4,372,945 and Armor *et al.*, US Patent 4,474,757.

The amount of the protein of the present invention present in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and whether or not the vaccine is adjuvanted. Generally, it is expected that each dose will comprise 1-1000 µg of protein, preferably 1-200 µg. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects will preferably receive a boost in about 4



weeks, followed by repeated boosts every six months for as long as a risk of allergic responses exists.

The vaccines of the present invention may be administered to adults or infants,  
5 however, it is preferable to vaccinate individuals soon after birth before the establishment of substantial Th2-type memory responses.

A further aspect of the invention provides a method of preventing or mitigating an allergic disease in man, which method comprises administering to a subject in need  
10 thereof an immunogenically effective amount of a mutated allergen of the invention, or of a vaccine in accordance with the invention.

The examples which follow are illustrative but not limiting of the invention. Restriction enzymes and other reagents were used substantially in accordance with the vendors'  
15 instructions.

#### **Example 1 - Expression in *Pichia pastoris*:**

##### **Construction of pNIV4811**

20 pNIV4811 is designed to promote the expression of mature Der p1 in fusion with the prepropeptide of *Pichia pastoris* MF $\alpha$ . Plasmid ATCC87307 contains the sequence for mature DerP1. The full Derp1 restriction map is given in figure 7.

Ligate with T4 DNA Ligase:

- 25                   - *SphI*-*XhoI* from pPIC9k (INVITROGEN V175-20)
- *XhoI*-*PstI* oligonucleotides whose sequences follow (n° 97038 and n° 97039)
- *PstI*-*XbaI* from pNIV4810 (plasmid ATCC87307)
- *AvrII*-*SphI* from pPIC9k

30   Sequences of the oligonucleotides:

n° 97038

5'TCGAGAAAAGAGAGGCTGAAGCTACTAACGCCTGCA3'

n° 97039

5'GGCGTTAGTAGCTTCAGCCTCTCTTTTC3'

### Results

*Pichia Pastoris* transfected with pNIV4811 leads to the expression of a protein of 43 kD, comprising uncleaved proMF $\alpha$ -mature Der p1 fusion protein, has been detected in several clones (Figure 1).

### Construction of pNIV4817

pNIV4817 is derived from pNIV4811. It is designed to promote the expression of the mature Der p1 in fusion with the prepeptide of *Pichia pastoris* MF $\alpha$ .

Ligate:

- *Bst*EII-*Bam*HI from pNIV4811
- *Bam*HI-*Pst*I oligonucleotides n° 97262 and n°97263 whose sequence follows
- *Pst*I-*Bst*EII from pNIV4811

### *Sequences of the oligonucleotides*

n° 97262

5'GATCCAAACGATGAGATTTCTTCAATTTTACTGCAGTTTATTCGC  
AGC ATCCTCCGCATTAGCTGCTCCAACAACTAACGCCTGCA3'

n° 97263

5'GGCGTTAGTTGGAGCAGCTAATGCGGAGGATGCTGCGAATAAACTGCAG  
TAAAAATTGAAGGAAATCTCATCGTTTG3'

### Results

Several clones expressed the mature form of Der p1 protein with an apparent molecular weight of 30 kDa, which was secreted into the supernatant (Figure 2).

### Construction of pNIV4815

Starting from pNIV4811, the following construction is designed to delete four residues [N-A-E-T (T is the first residue of the mature protein)] at the junction between the propeptide and the mature enzyme.

- Ligate :      *BlnI* - *BamHI* fragment from pPIC9k (the vector used for expression in *P. pastoris*)  
                  *BamHI* - *EaeI* fragment from pNIV4811  
                  *EaeI* - *EcoRI* fragment generated by RT-PCR with primers No 97142 and 97143. Residues : A<sub>6</sub> to E<sub>74</sub>.  
*EcoRI* - *PstI* oligonucleotides whose sequence follows (No 97140 and 97141). Residues : F<sub>75</sub> to C<sub>102</sub> except N<sub>96AET99</sub>  
*PstI* - *XbaI* fragment from pNIV4810.
- Sequence of the oligonucleotides allowing the NAET deletion:
- No 97140  
5'AATTCAAAAACCGATTTTTGATGAGTGCAGAAGCTTTTGAACACCTAAACTCAATTCGATTTGAACGCCTGCA<sup>3'</sup>      75 bases
- No 97141  
5'GGCGTTCAAATCGAATTGAGTTTTGAGGTGTTCAAAAGCTTCTGCATCATCAAAAATCGGTTTTTG<sup>3'</sup>      67 bases
- RT-PCR Primers
- No 97142  
5'CATGAAAATTGTTTTTGGCCATCGCC<sup>3'</sup>      25 bases  
  *EaeI*
- No 97143  
5'CGGTTTTTGAATTCATCCAACGAC<sup>3'</sup>      24 bases  
  *EcoRI*

### Construction of pNIV4819

Starting from pNIV4817, an expression plasmid designed to produce the mature form of Der p1 in *Pichia pastoris*, the following construction is made to replace the cysteine residue from the active site by an alanine residue (corresponding to the Cys 34 mutation in the mature protein).

5

Ligate: - *Bpu*1102I-*Ase*I fragment from pNIV4817  
 - *Ase*I-*Tfi*I synthetic fragment resulting from hybridization of oligonucleotides n° 97121 and n° 97122 whose sequence follows:  
 correspondig to residues I<sub>104</sub> to E<sub>142</sub> of the proDerP1 (I<sub>6</sub> of mature DerP1 protein)  
 - *Tfi*I-*Bst*EII fragment from pNIV4810 (ATCC 87307)  
 - *Bst*EII-*Bpu*1102I fragment from pNIV4817

10

#### *Sequences of the oligonucleotides*

15

n° 97121

5'TAATGGAAATGCTCCAGCTGAAATCGATTTGCGACAAATGCGAACTGTCA  
 CTCCCATTTCGTATGCAAGGAGGCTGTGGTTCAGCTTGGGCTTTCTCTGGTGT  
 TGCCGCAACTG<sup>3'</sup>

Ala 113 bases

20

n° 97122

5'ATTCAGTTGCGGCAACACCAGAGAAAGCCCA~~AA~~AGCTGAACCACAGCCTCC  
 TTGCATACGAATGGGAGTGACAGTTCGCATTTGTCGCAAATCGATTTTCAGCT  
 GGAGCATTTCCAT<sup>3'</sup>

114 bases

25

#### Construction of pNIV4815

Starting from pNIV4811, the following construction is made to delete four residues [N-A-E-T (T is the first residue of the mature protein)] at the junction between the  
 propeptide and the mature enzyme.

30

Ligate : *Bln*I - *Bam*HI fragment from pPIC9k (the vector used for expression in *PPi**Chia pastoris*)  
*Bam*HI - *Eae*I fragment from pNIV4811

*EaeI* - *EcoRI* fragment generated by RT-PCR with primers  
No 97142 and 97143. Residues : A<sub>6</sub> to E<sub>74</sub>.

*EcoRI* - *PstI* oligonucleotides whose sequence follows (No  
97140 and 97141). Residues : F<sub>75</sub> to C<sub>102</sub> except  
N96AET99

*PstI* - *XbaI* fragment from pNIV4810.

Sequence of the oligonucleotides : allowing the NAET deletion.

No 97140

10 5'AATTCAAAAACCGATTTTGTATGAGTGCAGAAGCTTTTGAACACCTCA  
AAACTCAATTCGATTTGAACGCCTGCA<sup>3'</sup> 75 bases

No 97141

5'GGCGTTCAAATCGAATTGAGTTTGTAGGTGTTCAAAGCTTCTGCACT  
CATCAAAAATCGGTTTTTG<sup>3'</sup> 67 bases

RT-PCR Primers

No 97142

5'CATGAAAATTGTTTTGGCCATCGCC<sup>3'</sup> 25 bases  
*EaeI*

No 97143

5'CGGTTTTTGAATTCATCCAACGAC<sup>3'</sup> 24 bases  
*EcoRI*

## Example 2 - Expression in mammalian cells

### Construction of pNIV4812

30 pNIV4812, an expression plasmid based on pEE14 (CellTech, Cockett *et al.*, 1990  
Biotechnology, vol 8,662-667) designed to produce the mature form of Der p1 in CHO-  
K1, codes for a pre-Der p1 followed by the mature Der p1 sequence (no pro-protein).

Ligate: - *HindIII*-*XbaI* from pEE14

35 - *HindIII*-*PstI* oligonucleotides n<sup>o</sup>97040 and 97041 whose  
sequence follows

-*Pst*I-*Xba*I from pNIV4810 (plasmid ATCC 87307)

*Sequence of the oligonucleotides*

5 n° 97040

5'AGCTTACCATGAAAATTGTTTTGGCCATCGCCTCATTGTTGGCATTGAGCG  
CTGTTTATGCTCGTACTAACGCCTGCA<sup>3'</sup>

n° 97041

10 5'GGCGTTAGTACGAGCATAAACAGCGCTCAATGCCAACAATGAGGCGATGG  
CCAAAACAATTTTCATGGTA<sup>3'</sup>

*Results*

The expression of a protein of an apparent molecular weight of 30 kDa has been  
15 detected in several extracts (Figure 3). No protein has been detected in the culture  
supernatants (data not shown), which suggests that the protein was not secreted from  
CHO-K1 cells.

20

Construction of pNIV4814

Starting from pNIV4812, the following construction is made to replace the cysteine  
residue from the active site by an alanine residue.

25

- Ligate :
- *Afl*III - *Ase*I fragment from pNIV4812.
  - *Ase*I-*Tfi*I oligonucleotides as in pNIV4819 construction (No  
97121 and 97122)
  - *Tfi*I - *Bst*EII fragment from pNIV4810 (ATCC 87307)
  - 30 - *Bst*EII - *Afl*III fragment from pNIV4812.

Construction of pNIV4819 and pNIV4814 was made possible, thanks to the discovery  
that in pNIV4810 the codon encoding isoleucine 6 of the mature protein was ATT

instead of ATC as published. This sequence is responsible for the presence of the *AseI* restriction site.

#### Construction of pNIV4816

5

Starting from pNIV4812, designed to expressed in CHO-K1, pNIV4816 has the same deletion as for pNIV4815. This construct results in the production of recombinant proDerP1 with the deletion of the NAET residues from the junction between the pro and mature protein.

10

Ligate :        *XbaI* - *AflIII* fragment from pEE14  
                       *AflIII* - *EaeI* fragment from pNIV4812  
                       *EaeI* - *EcoRI* fragment generated by RT-PCR using  
                       primers No 97142 and 97143  
                       *EcoRI* - *PstI* oligonucleotides No 97140 and 97141 (same  
                       oligonucleotides as used in pNIV4815)  
                       *PstI* - *XbaI* fragment from pNIV4810.

15

#### 20 Example 3 - Expression in Drosophila cells

#### Construction of pNIV4827

pNIV4827 has been designed to promote the expression and secretion of mature Der p1 from baculovirus infected insect cells.

25

Ligate :        pAcGP67A vector linearized with *PstI*  
                       *PstI* fragment from pNIV4810 (ATCC 87307)

The expression of Der p1 from pNIV4827 has been demonstrated by western blot.

30

#### Construction of pNIV4828

pNIV4828 has been designed to promote the expression and secretion of ProDer p1 from baculovirus infected insect cells.

- 5      Ligate :      *SapI*-*Bam*HI from pAcGP67A (Pharmingen ref. 21220P)  
                      *Bam*HI-*Eco*RI 172 bp synthetic fragment  
                      *Eco*RI-*Bss*SI from pNIV4820  
                      *Bss*SI-*Sap*I from pNIV4827

10      Sequence of the synthetic fragment :

a) coding oligonucleotide N° 97520

15      5' GAT CCC CGG CCG TCA TCG ATC AAA ACT TTT GAA GAA TAC AAA  
             AAA GCC TTC AAC AAA AGT TAT GCT ACC TTC GAA GAT GAA GAA  
             GCT GCC CGT AAA AAC TTT TTG GAA TCA GTA AAA TAT GTT CAA  
             TCA AAT GGA GGT GCC ATC AAC CAT TTG TCC GAT TTG TCG TTG GAT  
             G 3'

20      172 mer

b) complementary sequence N° 97521

25      5' AAT TCA TCC AAC GAC AAA TCG GAC AAA TGG TTG ATG GCA CCT  
             CCA TTT GAT TGA ACA TAT TTT ACT GAT TCC AAA AAG TTT TTA CGG  
             GCA GCT TCT TCA TCT TCG AAG GTA GCA TAA CTT TTG TTG AAG GCT  
             TTT TTG TAT TCT TCA AAA GTT TTG ATC GAT GAC GGC CGG G 3'

30      172 mer

The expression of ProDer p1 from pNIV4828 has been demonstrated by western blot.

35

#### Construction of pNIV4832

This plasmid codes for a Der p1 propeptide followed by the mature Der p1 (ProDer p1) sequence and is designed to be expressed in drosophila cells.

40

Ligate :      - *Asp*718-*Bam*HI fragment from expression vector pDS47/V5-His  
                      (INVITROGEN V4115-20)



- *Asp*718-*Spe*I synthetic fragment resulting from hybridization of 98023 and 98024 oligonucleotides
- *Spe*I-*Bgl*III fragment from pNIV4828

#### 5 *Sequences of the oligonucleotides*

n° 98023

5' GTA CCC TTA AGA TGC TA 3'

n° 98024

10 5' CTA GTA GCA TCT TAA GG 3'

NB : pNIV4828 is a plasmid designed for the isolation of recombinant baculoviruses expressing the pro-Derp 1 fused to gp67 signal peptide.

#### 15 *Results*

Transitory expression of pro-DerP1 in drosophila cells has been detected (data not shown).

20

#### Construction of pNIV4840

pNIV4840 differs from pNIV4832 in that the expression vector used is stable and  
25 inducible (pMT/V5-His)

Ligate : - *Asp*718-*Not*I fragment from pNIV4832

- *Not*I- *Asp*718 from pMT/V5-His (INVITROGEN V4120-20)

Expression of proDerp 1 in drosophila cells has been shown (Figure 4)

30

#### Construction of pNIV4842

pNIV4842 was designed to promote the expression and secretion of ProDer p1 from recombinant drosophila cells. ProDer p1 coding sequence was engineered to impair the cleavage of the propeptide. To achieve this goal, four nucleotide triplets coding for NAET including the cleavage site were deleted.

5

Ligate :       - NotI-EcoRI from pNIV4840  
                   - EcoRI-PstI synthetic fragment resulting from hybridization of  
                   oligonucleotides n°98136 and n°98137  
                   - PstI-BstEII from pNIV4840  
                   - BstEII-NotI from pNIV4840

10

#### *Sequence of the synthetic oligonucleotides*

##### a) Coding sequence

15 N° 98136

5' AAT TCA AAA ACC GAT TTT TGA TGA GTG CAG AAG CTT TTG AAC ACC  
 TCA AAA CTC AAT TCG ATT TGA ACG CCT GCA 3'

75 mer

##### Complementary sequence

20 N° 98137

5' GGC GTT CAA ATC GAA TTG AGT TTT GAG GTG TTC AAA AGC TTC TGC  
 ACT CAT CAA AAA TCG GTT TTT G 3'

67 mer

#### 25 *Results*

Detection of Der p1 in fusion with its propeptide has been detected in the supernatants after induction (Figure 5). The sequence of this recombinant mutant DerP1 is given in SEQ ID NO. 4.

#### 30 Construction of pNIV4843

pNIV4843 has been designed to promote the expression and secretion from recombinant drosophila cells of a ProDer p1 form in which the cysteine residue of the active site has been mutated to an alanine.

- Ligate :
- NotI-Asp718 from pMT/V5-His
  - Asp718-PstI from pNIV4832
  - PstI-TfII from pNIV4819
  - 5        - TfII-NotI from pNIV4832

### *Results*

Detection of Der p1 in fusion with its propeptide has been detected in the supernatants after induction (Figure 6). The sequence of this recombinant mutant DerP1 is given in  
 10    SEQ ID NO. 5.

### Example 3, Purification procedure of recombinant ProDer p1 secreted from recombinant drosophila cells

- 15    Proteins from the spent culture medium (1 liter) were concentrated at 4°C by overnight ammonium sulfate precipitation to 60% saturation. After centrifugation at 17000g during 30 min., the precipitate was resuspended in 20 ml of 20 mM Tris-HCl pH8.0 and dialyzed against 5 liters of the same buffer. Insoluble proteins were discarded by centrifugation at 20000g during 30 min. The dialysate was loaded onto a Q sepharose  
 20    XL column (3 x 1.6 cm, Pharmacia) equilibrated in 20 mM Tris-HCl pH8.0. After washing the column with the same buffer, bound proteins were eluted by steps of 100 mM increases of NaCl concentration. ProDer p1 mainly eluted at 200mM NaCl. Enriched ProDer p1 fractions were pooled and loaded onto an hydroxyapatite type 1 column (1 x 1.6 cm, Biorad) conditioned in 5 mM potassium phosphate buffer pH 7.0.  
 25    Unbound material containing ProDer p1 was concentrated by ultrafiltration using Omega membrane (cut-off : 10kD, Filtron). The concentrate was loaded onto a superdex 75 FPLC column (30 x 1 cm, Pharmacia) in PBS pH 7.3. Eluted ProDer p1 from the gel filtration column was more than 80% pure.

30

### Example 4, Vaccine formulation

Vaccines comprising the mutant DerP1 or allergens may be formulated with many common adjuvants. One preferred adjuvant system is an oil in water emulsion described below :

- 5 The oil in water emulsion adjuvant formulations used in the present invention are made comprising following oil in water emulsion component: 5% Squalene, 5%  $\alpha$ -tocopherol, 2.0% polyoxyethylene sorbitan monooleate (TWEEN 80). The emulsions are prepared as a 2 fold concentrate. All examples used in the immunological experiments are diluted with the addition of extra components and diluents to give  
10 either a 1x concentration (equating to a squalene:QS21 ratio (w/w) of 240:1) or further dilutions thereof.

- Briefly, TWEEN 80 is dissolved in phosphate buffered saline (PBS) to give a 2% solution in the PBS. To provide 100 ml of a two fold concentrate emulsion, 5ml of DL  
15  $\alpha$  tocopherol and 5ml of squalene are vortexed to mix thoroughly. 95ml of PBS/TWEEN solution is added to the oil and mixed thoroughly. The resulting emulsion is then passed through a syringe needle and finally microfluidised by using an M110S Microfluidics machine. The resulting oil droplets have a size of approximately 145-180 nm (expressed as z av. measured by PCS). The other adjuvant/vaccine  
20 components (QS21, 3D-MPL and antigen) are added to the emulsion in simple admixture.

- The antigen containing vaccines used herein are formulated either with full dose SB62 adjuvant to give a high squalene:QS21 ratio (240:1) or with a lower amount of SB62 to  
25 give a low ratio formulation (48:1). Other vaccines may optionally be formulated with the addition of cholesterol to the oil phase of the emulsion.

- These vaccines are assayed in groups of Balb/c mice. Briefly, groups of 10 mice are immunised intramuscularly 2 times at 3 weeks interval with 2  $\mu$ g mutant allergen  
30 combined with oil in water emulsion adjuvant. 14 days following the second immunisation the production of cytokines (IL-4, IL5 and IFN- $\gamma$ ) are analysed after *in vitro* restimulation of spleen and lymph nodes cells with allergen. Antibody response to wild-type allergen and the isotypic profile induced are monitored by ELISA at 21 days

post II and 14 days post IV.

005150 "09070360

## Claims

1. A recombinant substantially full length mutant allergen, wherein said mutant allergen has a reduced enzymatic activity compared to the wild-type allergen.
2. A recombinant mutant allergen as claimed in claim 1, wherein said allergen is a mutant of a type I cysteine protease allergen.
3. A recombinant mutant allergen as claimed in claim 1, wherein said allergen a mutant of DerP1 from *Dermatophagoides pteronyssinus*.
4. A recombinant mutant allergen as claimed in claim 3, wherein said mutant DerP1 comprises an active site mutant.
5. A recombinant mutant allergen as claimed in claim 4, wherein said active site mutant DerP1 comprises a mutation of the Cys 34 residue.
6. A recombinant mutant allergen as claimed in claim 5, wherein said mutation of the Cys 34 residue comprises an alanine substitution.
7. A recombinant mutant allergen as claimed in claim 4, wherein said active site mutant DerP1 comprises a mutation of the His 170 residue.
8. A recombinant mutant allergen as claimed in claim 3, wherein said mutant DerP1 comprises a mutation at the site of cleavage between the propeptide and the mature molecule.
9. A recombinant mutant allergen as claimed in claim 8, wherein said mutation at the site of cleavage between the propeptide and the mature molecule comprises a deletion of the residues NAET.
10. A recombinant mutant allergen as claimed in claim 3, wherein said mutation comprises the deletion or substitution of cysteine residues which are involved in disulphide bridge formation.
11. Stable recombinant proDerP1.
12. A recombinant mutant allergen having the sequence as set out in SEQ ID NO. 1
13. A recombinant mutant allergen having the sequence as set out in SEQ ID NO. 2
14. A recombinant mutant allergen having the sequence as set out in SEQ ID NO. 3
15. A recombinant mutant allergen having the sequence as set out in SEQ ID NO. 4
16. A recombinant mutant allergen having the sequence as set out in SEQ ID NO. 5

ART 34 AMDT

17. An isolated nucleic acid molecule encoding a mutated version of an allergen as claimed in any one of claims 1 to 16.
18. A vaccine comprising a recombinant mutant allergen as claimed in any one of claims 1 to 17, and an adjuvant.
19. A vaccine as claimed in claim 18, wherein the adjuvant is a preferential stimulator of Th1-type immune responses.
20. A vaccine as claimed in claim 18, wherein the adjuvant comprises one or both of QS21 and 3-O-deacylated monophosphoryl lipid A.
21. Use of a recombinant mutant allergen in the manufacture of a medicament for the treatment of allergy.
22. A method of treating or preventing allergic responses comprising administering to an individual suffering from or susceptible to allergy a vaccine as claimed in claim 18.

006750 0934560

AMENDED SHEET

FIGURE 1: Expression of a 43 kDa protein corresponding to mature Der p1 in fusion with the prepeptide MF-alpha of *Pichia pastoris* (construct pNIV4811) in yeast cells. The culture supernatants from various *Pichia pastoris* clones incubated in the absence or presence of methanol (methanol induction for 1 to 5 days indicated on the x axis) have been analyzed by SDS-PAGE and immunoblot analysis using an anti-Der p1 peptide (117-133) polyclonal antibody.





Figure 1



FIGURE 2: Expression of mature Der p1 (30 kDa) in fusion with the prepeptide of *Pichia pastoris* MF-alpha (construct pNIV4817) in yeast cells. The culture supernatants from *Pichia pastoris* cells incubated in the absence (J0) or presence of methanol for 1 day (J1) have been concentrated 50 times and, then, analyzed by SDS-PAGE and immunoblot analysis using an anti-Der p1 peptide (117-133) polyclonal antibody. Arrows indicate the mature Der p1 doublet at about 30 kDa



**Figure 2**

FIGURE 3: Expression of Der p1 in fusion with its propeptide (construct pNIV4812) in CHO-K1 cells. The cell extracts from different clones of CHO-K1 cells transfected with pNIV4812 (lanes 3-8) or transfected with the vector pEE14 alone as negative controls (lane 1 & 2) have been analyzed by SDS-PAGE and immunoblot analysis using an anti-Der p1 peptide (117-133) polyclonal antibody. The arrow indicates the mature Der p1 protein.




Figure 3

FIGURE 4: Expression of Der p1 in fusion with its propeptide (construct pNIV4840) in drosophila cells S2 (Invitrogen). The cell extracts of different clones of CHO-K1 cells transfected with pNIV4840 (lanes 1 & 4) or transfected with the inducible vector pMT/V5-His alone as negative controls (lanes 2,3,5, & 6) have been analyzed by SDS-PAGE and immunoblot analysis using an anti-Der p1 peptide (117-133) polyclonal antibody. The induction has been carried out for 22 hours (1-3) and 28 hours (4-6).




Figure 4

FIGURE 5: Expression of non-cleavable, non-activable Der p1 mutant in fusion with its pro-peptide (construct pNIV4842) in drosophila cells S2 (Invitrogen). The cell supernatants from transiently transfected S2 cells with pNIV4842 (lanes 1-4) or transfected with the inducible vector pMT/V5-His alone as negative control (lanes 5) have been analyzed by SDS-PAGE and immunoblot analysis using an anti-Der p1 peptide (117-133) polyclonal antibody. Lanes 1 to 4 correspond to 1, 4, 5, and 6 days of induction, respectively. Arrows indicate the pro Der p1 doublet at about 36 kDa.




Figure 5

FIGURE 6: Expression of non-active Der p1 mutant in fusion with its propeptide (construct pNIV4843) in drosophila cells S2. The cell supernatants from transiently transfected S2 cells with pNIV4843 (lanes 6-9) or transfected with the inducible vector pMT/V5-His alone as negative control (lanes 5) have been analyzed by SDS-PAGE and immunoblot analysis using an anti-Der p1 peptide (117-133) polyclonal antibody. Lanes 6 to 9 correspond to 1, 4, 5, and 6 days of induction, respectively. Arrows indicate the mature Der p1 doublet at about 36 kDa






Figure 6

Figure 7, Derp1 restriction map





06544560, 051900

a N V N K I R E A L A Q T H S A I A V I I -

5 CviJI  
HaeIII  
BccI  
EaeI  
GdiIII

10 SfaNI BsmI HgaI MslI | | | | |  
ThaI

GGCATCAAAGATTTAGACGCATTCCGTCATTATGATGGCCGAACAATCATTCAACGCGAT  
721 -----+-----+-----+-----+-----+ 780  
CCGTAGTTTCTAAATCTGCGTAAGGCAGTAATACTACCGGCTTGTAGTAAGTTGCGCTA

15 a G I K D L D A F R H Y D G R T I I Q R D -

BstEII  
MaeIII  
HincII  
MaeIII  
TaaI  
DraIII

20 AATGGTTACCAACCAACTATCAGCTGTCAACATTGTTGGTTACAGTAACGCACAAGGT  
781 -----+-----+-----+-----+-----+ 840  
TTACCAATGGTTGGTTTGATAGTGCAGAGTTGTAACAACCAATGTCATTGCGTGTCCA

25 a N G Y Q P N Y H A V N I V G Y S N A Q G -

CjeI  
TaaI  
BciVI  
CjePI  
AlwI  
RsaI  
SunI  
DpnI  
TaqI  
Sau3AI  
HgiEII  
MunI  
Tsp509I  
CjeI  
TaaI  
CjePI  
HphI  
BbvI  
MaeIII

30

35 GTCGATTATTGGATCGTACGAAACAGTTGGGATACCAATTGGGGTGATAATGGTTACGGT  
841 -----+-----+-----+-----+-----+ 900  
CAGCTAATAACCTAGCATGCTTTGTCAACCCCTATGGTTAACCCCACTATTACCAATGCCA

40 a V D Y W I V R N S W D T N W G D N G Y G -

Bsp24I  
Fnu4HI  
TseI  
ClaI  
TaqI  
CjePI  
CjeI  
MboII  
NdeI

45 TATTTTGCTGCCAACATCGATTTGATGATGATTGAAGAATATCCATATGTTGTCATTCTC  
901 -----+-----+-----+-----+-----+ 960  
ATAAAACGACGGTTGTAGCTAAACTACTACTAATTCTTATAGGTATACAACAGTAAGAG

50 a Y F A A N I D L M M I E E Y P Y V V I L -

TAA  
961 --- 963  
ATT

55

0054660 0946560



SEQ ID NO. 1

Sequence of full mutant DerP1 including pre-protein. Active site mutation Cys 132→Ala 132, corresponding to Cys34→Ala34 of the mature protein). Sequence includes coding and complementary DNA, and amino acid sequences.

5  
ATGAAAATTGTTTTGGCCATCGCCTCATTGTTGGCATTGAGCGCTGTTTATGCTCGTCCA 60  
-----+-----+-----+-----+-----+-----+  
TACTTTTAACAAAACCGGTAGCGGAGTAACAACCGTAACCTCGCGACAAATACGAGCAGGT  
M K I V L A I A S L L A L S A V Y A R P 20  
10  
TCATCGATCAAACTTTTGAAGAATACAAAAAGCCTTCAACAAAAGTTATGCTACCTTC 120  
-----+-----+-----+-----+-----+-----+  
AGTAGCTAGTTTTGAAAACCTTCTTATGTTTTTTCGGAAGTTGTTTTCAATACGATGGAAG  
S S I K T F E E Y K K A F N K S Y A T F 40  
15  
GAAGATGAAGAAGCTGCCCCGTAACCTTTTGAATCAGTAAAATATGTTCAATCAAAT 180  
-----+-----+-----+-----+-----+-----+  
CTTCTACTTCTTCGACGGGCATTTTTGAAAACCTTAGTCATTTTATACAAGTTAGTTTA  
E D E E A A R K N F L E S V K Y V Q S N 60  
20  
GGAGGTGCCATCAACCATTGTCCGATTTGTCGTTGGATGAATTCAAAAACCGATTTTTG 240  
-----+-----+-----+-----+-----+-----+  
CCTCCACGGTAGTTGGTAAACAGGCTAAACAGCAACCTACTTAAGTTTTTGGCTAAAAAC  
G G A I N H L S D L S L D E F K N R F L 80  
25  
ATGAGTGCAGAAGCTTTTGAACACCTCAAACTCAATTCGATTTGAATGCTGAAACTAAC 300  
-----+-----+-----+-----+-----+-----+  
TACTCACGTCTTCGAAAACCTTGTGGAGTTTGTAGTTAAGCTAAACTTACGACTTTGATTG  
M S A E A F E H L K T Q F D L N A E T N 100  
30  
GCCTGCAGTATCAATGGAAATGCTCCAGCTGAAATCGATTTGCGACAAATGCGAACTGTC 360  
-----+-----+-----+-----+-----+-----+  
CGGACGTCATAGTTACCTTTACGAGGTCGACTTTAGCTAAACGCTGTTTACGCTTGACAG  
A C S I N G N A P A E I D L R Q M R T V 120  
35  
ACTCCCATTTCGTATGCAAGGAGGCTGTGGTTACGCTTGGGGCTTTCTCTGGTGITGCCGCA 420  
-----+-----+-----+-----+-----+-----+  
TGAGGGTAAGCATACGTTTCTCCGACACCAAGT**CGA**ACCCGAAAGAGACCACAACGGCGT  
T P I R M Q G G C G S A W A F S G V A A 140  
40  
ACTGAATCAGCTTATTTGGCTTACCGTAATCAATCATTGGATCTTGCTGAACAAGAATTA 480  
-----+-----+-----+-----+-----+-----+  
TGACTTAGTTCGAATAAACCGAATGGCATTAGTTAGTAACCTAGAACGACTTGTTCTTAAT  
T E S A Y L A Y R N Q S L D L A E Q E L 160  
45  
GTCGATTGTGCTTCCCAACACGGTTGTCATGGTGATACCATTCCACGTGGTATTGAATAC 540  
-----+-----+-----+-----+-----+-----+  
CAGCTAACACGAAGGGTTGTGCCAACAGTACCCTATGGTAAGGTGCACCATAACTTATG  
V D C A S Q H G C H G D T I P R G I E Y 180  
50  
ATCCAACATAATGGTGTCTGTCCTCAAGAAAGCTACTATCGATACGTTGCACGAGAACAATCA 600  
-----+-----+-----+-----+-----+-----+  
TAGGTTGTATTACCACAGCAGGTTCTTTCGATGATAGCTATGCAACGTGCTCTTGTTAGT  
I Q H N G V V Q E S Y Y R Y V A R E Q S 200  
55  
TGCCGACGACCAAATGCACAACGTTTCGGTATCTCAAACCTATTGCCAAATTTACCCACCA 660

0954960.051900

-----+-----+-----+-----+-----+-----+-----+  
ACGGCTGCTGGTTTACGTGTTGCAAAGCCATAGAGTTTGATAACGGTTTAAATGGGTGGT 220  
C R R P N A Q R F G I S N Y C Q I Y P P  
5 AATGTAAACAAAATTCGTGAAGCTTTGGCTCAAACCCACAGCGCTATTGCCGTCATTATT 720  
-----+-----+-----+-----+-----+-----+-----+  
TTACATTTGTTTTAAGCACTTCGAAACCGAGTTTGGGTGTCGCGATAACGGCAGTAATAA 240  
N V N K I R E A L A Q T H S A I A V I I  
10 GGCATCAAAGATTTAGACGCATTCCGTCATTATGATGGCCGAACAATCATTCAACGCGAT 780  
-----+-----+-----+-----+-----+-----+-----+  
CCGTAGTTTCTAAATCTGCGTAAGGCAGTAATACTACCGGCTTGTTAGTAAGTTGCGCTA 260  
G I K D L D A F R H Y D G R T I I Q R D  
15 AATGGTTACCAACCAAACTATCACGCTGTCAACATTGTTGGTTACAGTAACGCACAAGGT 840  
-----+-----+-----+-----+-----+-----+-----+  
TTACCAATGGTTGGTTTGTAGTGCGACAGTTGTAACAACCAATGTCATTGCGTGTTCCTA 280  
N G Y Q P N Y H A V N I V G Y S N A Q G  
20 GTCGATTATTGGATCGTACGAAACAGTTGGGATACCAATTGGGGTGATAATGGTTACGGT 900  
-----+-----+-----+-----+-----+-----+-----+  
CAGCTAATAACCTAGCATGCTTTGTCAACCCTATGGTTAACCCCACTATTACCAATGCCA 300  
V D Y W I V R N S W D T N W G D N G Y G  
25 TATTTTGCTGCCAACATCGATTTGATGATGATTGAAGAATATCCATATGTTGTCATTCTC 960  
-----+-----+-----+-----+-----+-----+-----+  
ATAAAACGACGGTTGTAGCTAACTACTACTAACTTCTTATAGGTATACAACAGTAAGAG 320  
Y F A A N I D L M M I E E Y P Y V V I L  
30 TAA  
---  
ATT

35

005150" 0884550

SEQ ID NO. 2

5 Sequence of full mutant DerP1 including pre-protein containing a deletion at the  
propeptide cleavage site (NAET). Sequence includes coding and complementary DNA,  
and amino acid sequences.

ATGAAAATTGTTTGGCCATCGCCTCATTGTTGGCATTGAGCGCTGTTTATGCTCGTCCA 60  
-----+-----+-----+-----+-----+-----+-----+  
10 TACTTTTAAACAAAACCGGTAGCGGAGTAACAACCGTAACCTCGCGACAAATACGAGCAGGT  
M K I V L A I A S L L A L S A V Y A R P 20  
TCATCGATCAAACTTTTGAAGAATACAAAAAGCCTTCAACAAAAGTTATGCTACCTTC 120  
-----+-----+-----+-----+-----+-----+-----+  
15 AGTAGCTAGTTTTGAAAACCTTCTTATGTTTTTTCGGAAGTTGTTTTCAATACGATGGAAG  
S S I K T F E E Y K K A F N K S Y A T F 40  
GAAGATGAAGAAGCTGCCCCGTAAAACTTTTTGGAATCAGTAAAATATGTTCAATCAAAT 180  
-----+-----+-----+-----+-----+-----+-----+  
20 CTTCTACTTCTTCGACGGGCATTTTTGAAAAACCTTAGTCATTTTATACAAGTTAGTTTA  
E D E E A A R K N F L E S V K Y V Q S N 60  
GGAGGTGCCATCAACCATTTGTCCGATTTGTCGTTGGATGAATTCAAAAACCGATTTTTTG 240  
-----+-----+-----+-----+-----+-----+-----+  
25 CCTCCACGGTAGTTGGTAAACAGGCTAAACAGCAACCTACTTAAGTTTTTGGCTAAAAAC  
G G A I N H L S D L S L D E F K N R F L 80  
ATGAGTGCAGAAGCTTTTGAACACCTCAAACTCAATTCGATTTG AAC 300  
-----+-----+-----+-----+-----+-----+-----+  
30 TACTCACGTCTTCGAAAACCTTGTTGGAGTTTTGAGTTAAGCTAAAC TTG  
M S A E A F E H L K T Q F D L N 100  
GCCTGCAGTATCAATGGAAATGCTCCAGCTGAAATCGATTTGCGACAAATGCGAACTGTC 360  
-----+-----+-----+-----+-----+-----+-----+  
35 CGGACGTCATAGTTACCTTTACGAGGTGCACTTTAGCTAAACGCTGTTTACGCTTGACAG  
A C S I N G N A P A E I D L R Q M R T V 120  
ACTCCCATTCGTATGCAAGGAGGCTGTGGTTCATGTTGGGCTTTCTCTGGTGTGCGCA 420  
-----+-----+-----+-----+-----+-----+-----+  
40 TGAGGGTAAGCATACGTTCTCCGACACCAAGTACAACCCGAAAGAGACCACAACGGCGT  
T P I R M Q G G C G S C W A F S G V A A 140  
ACTGAATCAGCTTATTTGGCTTACCGTAATCAATCATTGGATCTTGCTGAACAAGAATTA 480  
-----+-----+-----+-----+-----+-----+-----+  
45 TGACTTAGTCGAATAAACCGAATGGCATTAGTTAGTAACCTAGAACGACTTGTCTTAAT  
T E S A Y L A Y R N Q S L D L A E Q E L 160  
GTCGATTGTGCTTCCCAACACGGTTGTTCATGGTGATACCATTCACGTGGTATTGAATAC 540  
-----+-----+-----+-----+-----+-----+-----+  
50 CAGCTAACACGAAGGGTTGTGCCAACAGTACCACTATGGTAAGGTGCACCATAACTTATG  
V D C A S Q H G C H G D T I P R G I E Y 180  
ATCCAACATAATGGTGTCTGCCAAGAAAGCTACTATCGATACGTTGCACGAGAACAATCA 600  
-----+-----+-----+-----+-----+-----+-----+  
55 TAGGTTGTATTACCACAGCAGGTTCTTTTCGATGATAGCTATGCAACGTGCTCTTGTTAGT  
I Q H N G V V Q E S Y Y R Y V A R E Q S 200

006750 0984560

TGCCGACGACCAAATGCACAACGTTTCGGTATCTCAAACCTATTGCCAAATTTACCCACCA 660  
-----+-----+-----+-----+-----+-----+  
ACGGCTGCTGGTTTACGTGTTGCAAAGCCATAGAGTTTGATAACGGTTTAAATGGGTGGT  
5 C R R P N A Q R F G I S N Y C Q I Y P P 220  
  
AATGTAAACAAAATTCGTGAAGCTTTGGCTCAAACCCACAGCGCTATTGCCGTCATTATT 720  
-----+-----+-----+-----+-----+-----+  
TTACATTTGTTTTAAGCACTTCGAAACCGAGTTTGGGTGTCGCGATAACGGCAGTAATAA  
10 N V N K I R E A L A Q T H S A I A V I I 240  
  
GGCATCAAAGATTTAGACGCATTCCGTCATTATGATGGCCGAACAATCATTCAACGCGAT 780  
-----+-----+-----+-----+-----+-----+  
CCGTAGTTTCTAAATCTGCGTAAGGCAGTAATACTACCGGCTTGTTAGTAAGTTGCGCTA  
15 G I K D L D A F R H Y D G R T I I Q R D 260  
  
AATGGTTACCAACCAAACCTATCACGCTGTCAACATTGTTGGTTACAGTAACGCACAAGGT 840  
-----+-----+-----+-----+-----+-----+  
TTACCAATGGTTGGTTTGATAGTGCGACAGTTGTAACAACCAATGTCATTGCGTGTTCCTA  
20 N G Y Q P N Y H A V N I V G Y S N A Q G 280  
  
GTCGATTATTGGATCGTACGAAACAGTTGGGATACCAATTGGGGTGATAATGGTTACGGT 900  
-----+-----+-----+-----+-----+-----+  
CAGCTAATAACCTAGCATGCTTTGTCAACCCTATGGTTAACCCCACTATTACCAATGCCA  
25 V D Y W I V R N S W D T N W G D N G Y G 300  
  
TATTTTGCTGCCAACATCGATTTGATGATGATTGAAGAATATCCATATGTTGTCATTCTC 960  
-----+-----+-----+-----+-----+-----+  
ATAAAACGACGGTTGTAGCTAAACTACTACTAACTTCTTATAGGTATACAACAGTAAGAG  
30 Y F A A N I D L M M I E E Y P Y V V I L 320  
  
TAA  
---  
ATT  
35

0954850-051300

SEQ ID NO. 3

Sequence of full mutant DerP1 including pre-protein. Active site mutation His 268 → Ala 268, corresponding to His170→Ala170 of the mature protein). Sequence includes coding and complementary DNA, and amino acid sequences.

ATGAAAATTGTTTTGGCCATCGCCTCATTGTTGGCATTGAGCGCTGTTTATGCTCGTCCA 60  
-----+-----+-----+-----+-----+-----+  
10 TACTTTTAACAAAACCGGTAGCGGAGTAACAACCGTAACCTCGCGACAAATACGAGCAGGT  
M K I V L A I A S L L A L S A V Y A R P 20  
TCATCGATCAAACTTTTGAAGAATACAAAAAGCCTTCAACAAAAGTTATGCTACCTTC 120  
-----+-----+-----+-----+-----+-----+  
15 AGTAGCTAGTTTTGAAACTTCTTATGTTTTTTCGGAAGTTGTTTTCAATACGATGGAAG  
S S I K T F E E Y K K A F N K S Y A T F 40  
GAAGATGAAGAAGCTGCCCCGTAAAACTTTTTGGAATCAGTAAATATGTTCAATCAAAT 180  
-----+-----+-----+-----+-----+-----+  
20 CTTCTACTTCTTCGACGGGCATTTTTGAAAACCTTAGTCATTTTATACAAGTTAGTTTA  
E D E E A A R K N F L E S V K Y V Q S N 60  
GGAGGTGCCATCAACCATTGTCCGATTGTGCGTTGGATGAATTCAAAAACCGATTTTTTG 240  
-----+-----+-----+-----+-----+-----+  
25 CCTCCACGGTAGTTGGTAAACAGGCTAAACAGCAACCTACTTAAGTTTTTGGCTAAAAAC  
G G A I N H L S D L S L D E F K N R F L 80  
ATGAGTGCAGAAGCTTTTGAACACCTCAAACTCAATTCGATTGGAATGCTGAAACTAAC 300  
-----+-----+-----+-----+-----+-----+  
30 TACTCACGTCTTCGAAAACCTTGTGGAGTTTTGAGTTAAGCTAACTTACGACTTTGATTG  
M S A E A F E H L K T Q F D L N A E T N 100  
GCCTGCAGTATCAATGGAAATGCTCCAGCTGAAATCGATTGCGACAAATGCGAACTGTC 360  
-----+-----+-----+-----+-----+-----+  
35 CGGACGTCATAGTTACCTTTACGAGGTCGACTTTAGCTAAACGCTGTTTACGCTTGACAG  
A C S I N G N A P A E I D L R Q M R T V 120  
ACTCCCATTTCGTATGCAAGGAGGCTGTGGTTCATGTTGGGCTTTCTCTGGTGTGCGCA 420  
-----+-----+-----+-----+-----+-----+  
40 TGAGGGTAAGCATACGTTCTCCGACACCAAGTACAACCCGAAAGAGACCACAACGGCGT  
T P I R M Q G G C G S C W A F S G V A A 140  
ACTGAATCAGCTTATTTGGCTTACCGTAATCAATCATTGGATCTTGCTGAACAAGAATTA 480  
-----+-----+-----+-----+-----+-----+  
45 TGACTTAGTCGAATAAACCGAATGGCATTAGTTAGTAACCTAGAACGACTTGTTCTTAAT  
T E S A Y L A Y R N Q S L D L A E Q E L 160  
GTCGATTGTGCTTCCCAACACGGTTGTCATGGTGATACCATTCACGTGGTATTGAATAC 540  
-----+-----+-----+-----+-----+-----+  
50 CAGCTAACACGAAGGGTTGTGCCAACAGTACCACTATGGTAAGGTGCACCATAACTTATG  
V D C A S Q H G C H G D T I P R G I E Y 180  
ATCCAACATAATGGTGTCTGCTCCAAGAAAGCTACTATCGATACGTTGCACGAGAACAATCA 600  
-----+-----+-----+-----+-----+-----+  
55 TAGGTTGTATTACCACAGCAGGTTCTTTCGATGATAGCTATGCAACGTGCTCTTGTTAGT  
I Q H N G V V Q E S Y Y R Y V A R E Q S 200  
TGCCGACGACCAAATGCACAACGTTTCGGTATCTCAAACCTATTGCCAAATTTACCCACCA 660

-----+-----+-----+-----+-----+-----+-----+  
ACGGCTGCTGGTTTACGTGTTGCAAAGCCATAGAGTTTGATAACGGTTTAAATGGGTGGT  
C R R P N A Q R F G I S N Y C Q I Y P P 220

5 AATGTAAACAAAATTCGTGAAGCTTTGGCTCAAACCCACAGCGCTATTGCCGTCATTATT 720  
-----+-----+-----+-----+-----+-----+-----+  
TTACATTTGTTTTAAGCACTTCGAAACCGAGTTTGGGTGTCGCGATAACGGCAGTAATAA  
N V N K I R E A L A Q T H S A I A V I I 240

10 GGCATCAAAGATTTAGACGCATTCCGTCATTATGATGGCCGAACAATCATTCAACGCGAT 780  
-----+-----+-----+-----+-----+-----+-----+  
CCGTAGTTTCTAAATCTGCGTAAGGCAGTAATACTACCGGCTTGTTAGTAAGTTGCGCTA  
G I K D L D A F R H Y D G R T I I Q R D 260

15 AATGGTTACCAACCAAACCTATGCTGCTGTCAACATTGTTGGTTACAGTAACGCACAAGGT 840  
-----+-----+-----+-----+-----+-----+-----+  
TTACCAATGGTTGGTTTGATACGACGACAGTTGTAACAACCAATGTCATTGCGTGTTCCA  
N G Y Q P N Y A A V N I V G Y S N A Q G 280

20 GTCGATTATTGGATCGTACGAAACAGTTGGGATACCAATTGGGGTGATAATGGTTACGGT 900  
-----+-----+-----+-----+-----+-----+-----+  
CAGCTAATAACCTAGCATGCTTTGTCAACCCTATGGTTAACCCCACTATTACCAATGCCA  
V D Y W I V R N S W D T N W G D N G Y G 300

25 TATTTTGCTGCCAACATCGATTTGATGATGATTGAAGAATATCCATATGTTGTCATTCTC 960  
-----+-----+-----+-----+-----+-----+-----+  
ATAAAACGACGGTTGTAGCTAAACTACTACTAATTCTTATAGGTATACAACAGTAAGAG  
Y F A A N I D L M M I E E Y P Y V V I L 320

30 TAA  
---  
ATT

0054960 09845560

SEQ ID NO. 4

Amino acid sequence for the mutant DerP1 as encoded by pNIV4842, and shown in figure 5.

5

1 MLLVNQSHQG FNKEHTSKMV SAIVLYVLLA AAAHSAFAAD PRPSSIKTFE

51 EYKKAFNKSY ATFEDEEAAR KNFLESVKYV QSNGGAINHL SDLSLDEFKN

10

101 RFLMSAEAFE HLKTQFDLNA CSINGNAPAE IDLRQMRTVT PIRMQGGCGS

151 CWAFIGVAAT ESAYLAYRNQ SLDLAEQELV DCASQHGCHG DTIPRGIEYI

15

201 QHNGVVQESY YRYVAREQSC RRPNAQRFGI SNYCQIYPPN ANKIREALAQ

251 THSAIAVIIG IKDLDAFRHY DGRTHQRDN GYQPNYHAVN IVGYSNAQGV

301 DYWIVRNSWD TNWGDNGYGY FAANIDLMMI EEYPYVVIL\*

20

005T50"0904560

SEQ ID NO. 5

Amino acid sequence for the mutant DerP1 as encoded by pNIV4843, and shown in figure 6.

5  
1 MLLVNQSHQG FNKEHTSKMV SAIVLYVLLA AAAHSAFAAD PRPSSIKTFE  
51 EYKKAFNKS Y ATFEDDEEAAR KNFLESVKYV QSNGGAINHL SDLSLDEFKN  
10 101 RFLMSAEAFE HLKTQFDLNA ETNACSINGN APAEIDLRQM RTVTPIRMQG  
151 GCGSAWAFSG VAATESAYLA YRNQSLDLAE QELVDCASQH GCHGDTIPRG  
201 IEYIQHNGVV QESYYRYVAR EQSCRRPNAQ RFGISNYCQI YPPNANKIRE  
15 251 ALAQTHSAIA VIIGIKDLDA FRHYDGRTH QRDNGYQPNY HAVNIVGYSN  
301 AQGV DYWIVR NSWDTNWGDN GYGYFAANID LMMIEEYPYV VIL\*

20

006750 0984560



## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

RECOMBINANT ALLERGEN WITH REDUCED ENZYMATIC ACTIVITY

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 16 November 1998 as Serial No. PCT/EP98/07521  
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
GB 9724531.0	Great Britain	19 November 1997	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

006150 09845500


I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to ZOLTAN KEREKES, SmithKline Beecham Corporation, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5024.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Claudine BRUCK


Inventor's Signature:  Date: May 5, 2000

Residence: RIXENSART, BELGIUM BEX

Citizenship: BELGIAN

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

Full Name of Inventor: Alex BOLLEN

Inventor's Signature:  Date: May 11, 2000

Residence: ITTERBEEK, BELGIUM BEX


Citizenship: BELGIAN

Post Office Address: SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

100  
09654660-051506  
200

3-00

Full Name of Inventor: Paul JACOBS

Inventor's Signature: 

Date: 11/05/00

Residence:

LANQUESAINT, BELGIUM

JACOBS. P.

BEX

Citizenship:


BELGIAN

Post Office Address:

SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

4-00

Full Name of Inventor: Marc Georges Francis MASSAER

Inventor's Signature: 

Date: 11.05.2000

Residence:

BRAINE LE CHATEAU, BELGIUM

BEX

Citizenship:

BELGIAN

Post Office Address:

SmithKline Beecham Corporation  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, Pennsylvania 19406-0939

005150 0934550